Nascent Biotech, Inc. and HypoSpray Pharma announced a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab ("PTB"), Nascent's lead monoclonal antibody cancer treatment asset, which is now in Phase II clinical research for the treatment of Brain Cancer. Once successfully commercialized, the Company hopes to eliminate bi-weekly weekly infusions, allowing patients to administer Pritumumab and avoid inconvenient, tedious, and uncomfortable multi hour cancer center treatment visits. HypoSpray Pharma of Palm Beach Gardens FL has developed innovative technology for delivering active ingredients across the skin and mucosa.

The company has a Drug Master File of record with the FDA for its delivery system, which enables measured application of a biological peptide to mucosal membranes or intact skin, promoting rapid absorption and bioavailability.